优赫得一线治疗HER2突变晚期非鳞状NSCLC中位PFS达14.3个月

证券日报09-16 14:05

9月14日，国际肺癌研究协会2026世界肺癌大会正在召开。会上，阿斯利康和第一三共公布了代号为DESTINY-Lung04的III期临床研究结果。研究显示，优赫得（注射用德曲妥珠单抗）一线治疗不可切除的局部晚期或转移性HER2突变非鳞状非小细胞肺癌（NSCLC）患者，与全球标准治疗方案（铂类-培美曲塞双药化疗联合帕博利珠单抗）相比，在无进展生存期（PFS）方面取得了具有统计学意义和临床意义的改善。...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohunote.com/m/news/2667367005?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-09-16 14:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2667367005","market":"sh","top_or_hot":-1,"title":"优赫得一线治疗HER2突变晚期非鳞状NSCLC中位PFS达14.3个月","media":"证券日报","content":"<div>\n<p>9月14日，国际肺癌研究协会2026世界肺癌大会正在召开。会上，阿斯利康和第一三共公布了代号为DESTINY-Lung04的III期临床研究结果。研究显示，优赫得（注射用德曲妥珠单抗）一线治疗不可切除的局部晚期或转移性HER2突变非鳞状非小细胞肺癌（NSCLC）患者，与全球标准治疗方案（铂类-培美曲塞双药化疗联合帕博利珠单抗）相比，在无进展生存期（PFS）方面取得了具有统计学意义和临床意义的改善。...</p>\n\n<a href=\"http://finance.eastmoney.com/a/202609163875988974.html\">网页链接</a>\n\n</div>\n","source":"stock_eastmoney","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>优赫得一线治疗HER2突变晚期非鳞状NSCLC中位PFS达14.3个月</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n优赫得一线治疗HER2突变晚期非鳞状NSCLC中位PFS达14.3个月\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-09-16 14:05 北京时间&nbsp;&nbsp;&nbsp;<a href=http://finance.eastmoney.com/a/202609163875988974.html><strong>证券日报</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>9月14日，国际肺癌研究协会2026世界肺癌大会正在召开。会上，阿斯利康和第一三共公布了代号为DESTINY-Lung04的III期临床研究结果。研究显示，优赫得（注射用德曲妥珠单抗）一线治疗不可切除的局部晚期或转移性HER2突变非鳞状非小细胞肺癌（NSCLC）患者，与全球标准治疗方案（铂类-培美曲塞双药化疗联合帕博利珠单抗）相比，在无进展生存期（PFS）方面取得了具有统计学意义和临床意义的改善。...</p>\n\n<a href=\"http://finance.eastmoney.com/a/202609163875988974.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ADC","symbol_name":"艾格里房产","start_time":0,"source_url":"http://finance.eastmoney.com/a/202609163875988974.html","article_id":"2667367005","we_media_id":null,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609163875988974.html","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2667367005","pubTimestamp":1789538700,"columns":[],"sourceInfo":{"source_id":"stock_eastmoney","name":"东方财富"},"weMediaInfo":null,"summary":"9月14日，国际肺癌研究协会2026世界肺癌大会正在召开。会上，阿斯利康和第一三共公布了代号为DESTINY-Lung04的III期临床研究结果。","collect":0,"end_time":0,"defaultTopTitle":"eastmoney.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"ADC":"艾格里房产","NETL":"NETLease Corporate Real Estate ETF","BK4211":"区域性银行","BK4231":"零售房地产信托","BK4080":"零售业房地产投资信托","PFS":"Provident Financial Services Inc","BK4195":"互助储蓄与抵押信贷金融服务"},"translate_title":"Median PFS of 14.3 months in first-line treatment of advanced non-squamous NSCLC with HER2 mutation","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PFS":1,"ADC":1,"NETL":0.6},"content_text":"9月14日，国际肺癌研究协会2026世界肺癌大会正在召开。会上，阿斯利康和第一三共公布了代号为DESTINY-Lung04的III期临床研究结果。研究显示，优赫得（注射用德曲妥珠单抗）一线治疗不可切除的局部晚期或转移性HER2突变非鳞状非小细胞肺癌（NSCLC）患者，与全球标准治疗方案（铂类-培美曲塞双药化疗联合帕博利珠单抗）相比，在无进展生存期（PFS）方面取得了具有统计学意义和临床意义的改善。　　德曲妥珠单抗是一款靶向HER2的抗体偶联药物（ADC），由第一三共研制，并由阿斯利康和第一三共合作开发和商业化。截至目前，该药已在全球超过80个国家和地区获批用于经治HER2突变不可切除或转移性NSCLC成人患者。　　阿斯利康方面表示，DESTINY-Lung04是首项在HER2突变晚期NSCLC患者中证实PFS优于全球一线标准治疗的III期临床研究，相关结果将进一步支持德曲妥珠单抗作为HER2基因突变患者治疗选择的潜力。　　进一步来看，DESTINY-Lung04是一项全球随机、开放性III期临床研究，共入组454例患者，按照1：1随机接受德曲妥珠单抗或标准治疗，主要终点为经盲态独立中心审查（BICR）评估的PFS。研究结果显示，德曲妥珠单抗组中位PFS为14.3个月，帕博利珠单抗联合化疗组为8.3个月，前者延长6个月；德曲妥珠单抗将疾病进展或死亡风险降低37%。（文章来源：证券日报）","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.0","shortVersion":"4.50.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2667367005","isCrawlerRequest":true}